title: Investigation of possible interference by digoxin-like immunoreactive substances on the Architect iDigoxin CMIA in serum samples from pregnant women, and patients with liver disease, renal insufficiency, critical illness, and kidney and liver transplant.
abstract: BACKGROUND
  Although the possible interference of digoxin-like immunoreactive substances (DLIS) on the Architect iDigoxin chemiluminiscent microparticle immunoassay (CMIA) has been emphasized by the manufacturer, a specific study about this subject has still not been carried out.
  
  
  METHODS
  Apparent serum digoxin concentrations were determined using the Architect iDigoxin CMIA from Abbott Laboratories in digoxin-free pregnant women (n = 50), and patients with liver disease (n = 50), renal insufficiency (n = 50), kidney (n = 25) or liver (n = 25) transplant, and critical illness (n = 50).
  
  
  RESULTS
  In all of the patients included in this study, apparent serum digoxin concentrations were lower than the correspondent quantification limit (< 0.30 microg/L).
  
  
  CONCLUSIONS
  The Architect iDigoxin CMIA assay would be relatively free from endogenous DLIS positive interferences.
authors.affiliation: Unidad Monitorización Fármacos, Laboratorio Central, Hospital Clínico Universitario, Instituto de Investigación Sanitaria (IDIS), 15706 Santiago de Compostela, Spain.
authors.forename: Natalia
authors.initials: N
authors.lastname: Lampon
authors.forename: Fernando
authors.initials: F
authors.lastname: Pampin
authors.forename: J Carlos
authors.initials: JC
authors.lastname: Tutor
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016638:Critical Illness; D004077:Digoxin / Q000097:blood*; D005260:Female; D006801:Humans; D016030:Kidney Transplantation; D008107:Liver Diseases / Q000097:blood*; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D011247:Pregnancy / Q000097:blood*; D051437:Renal Insufficiency / Q000097:blood*
chemical_list: D004077:Digoxin